Overview

* Reviva reports Q3 net loss of $4 mln, improved from $8.4 mln loss last year

* Company plans pre-NDA meeting with FDA for brilaroxazine in Q4 2025

* European patent granted for brilaroxazine in pulmonary fibrosis

Outlook

* Company plans pre-NDA meeting with FDA for brilaroxazine in Q4 2025

Result Drivers

* EQUITY OFFERING - Raised $9 mln through public equity offering to support ongoing research and development

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 EPS -$0.06

Q3 Net -$4 mln

Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Reviva Pharmaceuticals Holdings Inc ( RVPH ) is $3.00, about 80.7% above its November 12 closing price of $0.58

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)